{"blog": [], "keywords": [{"value": "Sanofi SA", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "MannKind Corporation", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Mann, Alfred E", "name": "persons", "rank": "3", "is_major": "N"}, {"value": "Pfizer Inc", "name": "organizations", "rank": "4", "is_major": "N"}, {"value": "Food and Drug Administration", "name": "organizations", "rank": "5", "is_major": "N"}, {"value": "Diabetes", "name": "subject", "rank": "6", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/01/06/business/sanofi-ends-marketing-deal-with-developer-of-inhaled-insulin.html", "document_type": "article", "byline": {"person": [{"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 1}], "original": "By ANDREW POLLACK"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/01/06/business/06Insulin/06Insulin-thumbWide.jpg", "legacy": {"wide": "images/2016/01/06/business/06Insulin/06Insulin-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/01/06/business/06Insulin/06Insulin-articleLarge.jpg", "legacy": {"xlarge": "images/2016/01/06/business/06Insulin/06Insulin-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/01/06/business/06Insulin/06Insulin-thumbStandard-v2.jpg", "legacy": {"thumbnail": "images/2016/01/06/business/06Insulin/06Insulin-thumbStandard-v2.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "914", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent.", "pub_date": "2016-01-06T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Shares of Inhaled Insulin Maker Plummet 48% as Big Marketing Partner Pulls Out", "main": "Sanofi Ends Marketing Deal With Developer of Inhaled Insulin"}, "print_page": "2", "snippet": "The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent.", "_id": "568c05fb38f0d803f4a0c464", "slideshow_credits": null, "abstract": "Insulin developer MannKind announces that Sanofi is ending agreement in which it had rights to market inhaled insulin called Afrezza; drug has not met sales expectations since Food and Drug Administration approval."}